

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



利君國際醫藥(控股)有限公司

Lijun International Pharmaceutical (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

ANNOUNCEMENT EXTENSIONS OF LONG STOP DATES OF SALE AND PURCHASE AGREEMENTS

The Board announces that it has been informed by the substantial shareholders of the Company, namely, Prime United Industries and China Pharmaceutical, that each of the Vendors has respectively agreed with the Purchaser to extend the Long Stop Date of each respective Agreement to on or before 31 August 2013.

References are made to the announcements of the Company dated 28 December 2012, 3 January 2013 and 6 May 2013 (the “**Announcements**”) pursuant to which, among other things, the Company was informed that each of Prime United Industries and China Pharmaceutical, as Vendors and as substantial shareholders of the Company, had entered into an Agreement with Sichuan Kelun Pharmaceutical Co., Ltd., as Purchaser, respectively, pursuant to which each of Prime United Industries and China Pharmaceuticals has agreed to sell to the Purchaser 180,000,000 shares and 180,000,000 shares of the Company at HK\$2.9167 per share (representing approximately 6.14% and 6.14% of the issued share capital of the Company respectively as at the date of this announcement). Capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements unless otherwise stated.

Pursuant to the terms of each Agreement, if all conditions precedent set out therein cannot be fulfilled in full or waived or exempted before 30 June 2013 (the “**Long Stop Date**”) or such other date as agreed between the Purchaser and each respective Vendor in writing, the Agreement shall be terminated immediately.

As additional time is required to fulfill certain conditions precedent and that such conditions precedent cannot be waived or exempted pursuant to the terms of each Agreement, the Company was informed by Prime United Industries and China Pharmaceutical that each of the Vendors has respectively agreed with the Purchaser to extend the Long Stop Date of each respective Agreement to on or before 31 August 2013 or such later date as the Purchaser and each of the Vendors may respectively agree in writing.

As the conditions precedent may or may not be fulfilled, shareholders of the Company and potential investors are advised to exercise caution in dealing in the shares of the Company.

By Order of the Board
Chan Ka Kit
Company Secretary

Hong Kong, 28 June 2013

As at the date of this announcement, the Board comprises Mr. Wu Qin, Mr. Qu Jiguang, Mr. Xie Yunfeng, Mr. Wang Xianjun and Mr. Duan Wei as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.

All the Directors jointly and severally accept full responsibility for the accuracy of information contained in this announcement and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.